TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
IRVINE, Calif., Nov. 17, 2017 -- MRI Interventions, Inc. (OTCQB:MRIC), today announced that Joe Burnett, CEO, will present at the 10th Annual LD Micro Main Event Conference on Wednesday, December 6, 2017, at 11:00 am Pacific Time. The event will be held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Management will be available to meet with investors throughout the day. Investors wishing to schedule a meeting should contact LD Micro or MRI Interventions Investor Relations at [email protected].
About MRI Interventions, Inc.
Building on the imaging power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Forward-Looking Statements
Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, both of which have been filed with the Securities and Exchange Commission.
Contact Information:
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
[email protected]
